DESTINY-Breast03: Efficacy Results (July 25, 2022 DCO Date)
Progression-Free Survival1,2
-
PFS by BICR
-
PFS by Investigator Assessment
-
PFS by Subgroups
PFS by BICR1,2
PFS by BICR1,2
![<p>PFS by BICR<span class="tooltip"><span class="tooltip-text"><sup>1,2</sup></span><span class="tooltip-content" style="display: none;"><span>1. Hurvitz SA, Hegg R, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial [article]. <em>The Lancet</em>. 2022;401(10371):105-117.</span><span>2. Hurvitz SA, Hegg R, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results of the randomized, phase 3 study DESTINY-Breast03 [presentation and supplementary material]. Presented at: San Antonio Breast Cancer Symposium (SABCS) 2022 Annual Meeting; December 6-10, 2022.</span></span></span></p>](/content/dam/intelligentcontent/docuvera/assets/global/trastuzumab-deruxtecan/8db67364-6c52-4ea0-b987-9d4900884ec2/b1a5e37f-5f0c-4a39-931d-b8e2d5c1438e.png)
a Two-sided, from stratified log-rank test
b Nominal P value
PFS by Investigator Assessment1-3
PFS by Investigator Assessment1-3
![<p>PFS by Investigator Assessment<span class="tooltip"><span class="tooltip-text"><sup>1-3</sup></span><span class="tooltip-content" style="display: none;"><span>1. Hurvitz SA, Hegg R, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial [article]. <em>The Lancet</em>. 2022;401(10371):105-117.</span><span>2. Hurvitz SA, Hegg R, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results of the randomized, phase 3 study DESTINY-Breast03 [presentation and supplementary material]. Presented at: San Antonio Breast Cancer Symposium (SABCS) 2022 Annual Meeting; December 6-10, 2022.</span><span>3. Hurvitz SA, Hegg R, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial [supplementary material]. <em>The Lancet</em>. 2022;401(10371):105-117.</span></span></span></p>](/content/dam/intelligentcontent/docuvera/assets/global/trastuzumab-deruxtecan/8db67364-6c52-4ea0-b987-9d4900884ec2/84546fdc-412b-4674-9dd5-a66e537b4d9f.png)
a Two-sided
b Nominal P value
PFS by Subgroups3
PFS by Subgroups3
![<p>PFS by Subgroups<span class="tooltip"><span class="tooltip-text"><sup>3</sup></span><span class="tooltip-content" style="display: none;"><span>3. Hurvitz SA, Hegg R, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial [supplementary material]. <em>The Lancet</em>. 2022;401(10371):105-117.</span></span></span></p>](/content/dam/intelligentcontent/docuvera/assets/global/trastuzumab-deruxtecan/8db67364-6c52-4ea0-b987-9d4900884ec2/eb24a91e-6399-450a-a5b7-3dc407a9abb1.png)
a Prior lines of systemic therapy not including hormone therapy
Overall Survival1,2
-
Kaplan-Meier Analysis
-
OS by Subgroups
OS.1,2
OS.1,2
![<p>OS.<span class="tooltip"><span class="tooltip-text"><sup>1,2</sup></span><span class="tooltip-content" style="display: none;"><span>1. Hurvitz SA, Hegg R, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial [article]. <em>The Lancet</em>. 2022;401(10371):105-117.</span><span>2. Hurvitz SA, Hegg R, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results of the randomized, phase 3 study DESTINY-Breast03 [presentation and supplementary material]. Presented at: San Antonio Breast Cancer Symposium (SABCS) 2022 Annual Meeting; December 6-10, 2022.</span></span></span></p>](/content/dam/intelligentcontent/docuvera/assets/global/trastuzumab-deruxtecan/8db67364-6c52-4ea0-b987-9d4900884ec2/42818c5c-0064-4c53-83e3-7aa60b77d5ce.png)
Note: There were 19 patients (7.3%) treated with T-DXd and 28 patients (10.6%) treated with T-DM1 who were lost to follow-up.
a The P value for overall survival crossed the prespecified boundary (p=0.013) and was statistically significant
b Two-sided from stratified log-rank test
OS by Subgroups.1,2
OS by Subgroups.1,2
![<p>OS by Subgroups.<span class="tooltip"><span class="tooltip-text"><sup>1,2</sup></span><span class="tooltip-content" style="display: none;"><span>1. Hurvitz SA, Hegg R, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial [article]. <em>The Lancet</em>. 2022;401(10371):105-117.</span><span>2. Hurvitz SA, Hegg R, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results of the randomized, phase 3 study DESTINY-Breast03 [presentation and supplementary material]. Presented at: San Antonio Breast Cancer Symposium (SABCS) 2022 Annual Meeting; December 6-10, 2022.</span></span></span></p>](/content/dam/intelligentcontent/docuvera/assets/global/trastuzumab-deruxtecan/8db67364-6c52-4ea0-b987-9d4900884ec2/514c60f5-e7a5-447b-b18f-254cafcab688.jpeg)
a Prior lines of systemic therapy not including hormone therapy
Antitumor Response1,2
Antitumor Response1,2
Antitumor Response1,2
![<p>Antitumor Response<span class="tooltip"><span class="tooltip-text"><sup>1,2</sup></span><span class="tooltip-content" style="display: none;"><span>1. Hurvitz SA, Hegg R, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial [article]. <em>The Lancet</em>. 2022;401(10371):105-117.</span><span>2. Hurvitz SA, Hegg R, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results of the randomized, phase 3 study DESTINY-Breast03 [presentation and supplementary material]. Presented at: San Antonio Breast Cancer Symposium (SABCS) 2022 Annual Meeting; December 6-10, 2022.</span></span></span></p>](/content/dam/intelligentcontent/docuvera/assets/global/trastuzumab-deruxtecan/8db67364-6c52-4ea0-b987-9d4900884ec2/8e4db206-ea54-476b-801f-6aa8d38e10c6.png)
Note: Red line at 20% indicates progressive disease; black line at −30% indicates partial response.
Abbreviations
BICR = blinded independent central review
;BM = brain metastases
;CI = confidence interval
;DCO = data cut-off
;HR = hazard ratio
;mPFS = median progression-free survival
;NE = not evaluable
;NR = not reached
;OS = overall survival
;PFS = progression-free survival
;T-DM1 = trastuzumab emtansine
;T-DXd = trastuzumab deruxtecan
References
1. Hurvitz SA, Hegg R, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial [article]. The Lancet. 2022;401(10371):105-117.
2. Hurvitz SA, Hegg R, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results of the randomized, phase 3 study DESTINY-Breast03 [presentation and supplementary material]. Presented at: San Antonio Breast Cancer Symposium (SABCS) 2022 Annual Meeting; December 6-10, 2022.
3. Hurvitz SA, Hegg R, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial [supplementary material]. The Lancet. 2022;401(10371):105-117.
Please note that this content may contain some data and/or patient populations which are considered off-label in your country. Providing this information does not constitute any recommendation for use. AstraZeneca is providing this material as an information service and professional courtesy.
To help us improve our content for health care professionals, please take this short survey.
Document ID: 8db67364-6c52-4ea0-b987-9d4900884ec2
Last updated: 27-June-2024
©2023 AstraZeneca. All rights reserved.